Clinical trials: Affective Disorder
Depressive Disorder, Major
Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained release (DVS SR) or placebo for 12 weeks.
- Trial name
- NCT00824291
- Testing
- desvenlafaxine succinate sustained release, Genotyping
- Volunteers
- 437 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work.
- Trial name
- NCT06280235
- Testing
- BI 1569912
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Premature Birth, Pregnancy Preterm
Engaging Mothers & Babies; Reimagining Antenatal Care for Everyone (EMBRACE) Study
This is a randomized comparative effectiveness study of two forms of enhanced prenatal care among 674 Medi-Cal eligible pregnant individuals in Fresno, California.
- Conditions
- Premature Birth, Pregnancy Preterm, Prenatal Stress, Depression, Anxiety
- Trial name
- EMBRACE (NCT04154423)
- Testing
- Glow! Group Prenatal Care, Individual Prenatal Care with CPSP
- Where
- 2 sites in United States
- Volunteers
- 678 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Depression, Dysthymic Disorder
Duloxetine Treatment in Elderly With Dysthymia
Dysthymic disorder (DD) denotes chronic depression with fewer symptoms than major depressive disorder (MDD), and it affects ~ 2-4 % of adults with a similar prevalence in the elderly.
- Trial name
- NCT01852383
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
rTMS for Depressed Teens: A Sham-Controlled Trial, Part 2
This research proposal aims to better understand the neurobiology of depression in adolescents and how repetitive transcranial magnetic stimulation (rTMS) may therapeutically impact brain function and mood.
- Trial name
- NCT01804296
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Paul E. Croarkin
Major Depressive Disorder
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
This is a study with an Open-Label (OL) phase followed by a randomized, Double-Blind (DB), placebo-controlled phase to assess efficacy and safety of SAGE-217 on relapse prevention in adults with major depressive disorder (MDD).
- Trial name
- NCT04007367
- Testing
- SAGE-217
- Where
- 46 sites in United States
- Volunteers
- 53 people
- Sponsor
- Biogen
Depressive Disorder, Major
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).
- Trial name
- NCT03614156
- Testing
- Rapastinel
- Where
- 52 sites in United States, Hungary and 3 more
- Volunteers
- 363 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Psychosis, Schizophrenia
Levetiracetam in Early Psychosis
In order to establish target engagement and identify an effective dose the investigators will conduct a placebo-controlled single-dose parallel group trial of levetiracetam 185 mg and 500 mg in 24 medication-naïve early psychosis…
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Schizophreniform
- Trial name
- NCT03129360
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Depression
Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.
- Trial name
- PROTECT (NCT00536172)
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Nebraska
Psychosis, Substance Use
Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study
The purpose of this study is to evaluate Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) for families experiencing early psychosis and substance use delivered exclusively or primarily via telehealth…
- Conditions
- Psychosis, Substance Use, Substance Use Disorders, Family
- Trial name
- NCT05380583
- Testing
- CRAFT-EP, TAU
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Schizophrenia, Bipolar Disorder
Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness
The purpose of this study is to evaluate the effectiveness of a mobile real-time cognitive behavioral intervention for serious mental illness (SMI) and to identify the facilitators, barriers, and costs of implementation.
- Trial name
- NCT02035202
- Testing
- CBT2go, Smartphone
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- University of California, San Diego
Major Depressive Disorder
A Study in Depression and Associated Painful Physical Symptoms
The purpose of this study is to find out if 60 mg of duloxetine given once a day by mouth for 8 weeks to patients diagnosed with major depressive disorder, who also report associated painful physical symptoms, is better than…
- Trial name
- NCT01070329
- Testing
- Duloxetine
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 527 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158546
- Testing
- ALKS 5461
- Where
- 58 sites in United States, Bulgaria
- Volunteers
- 447 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00672620
- Testing
- Vortioxetine, Duloxetine
- Where
- 38 sites in United States
- Volunteers
- 611 people
- Sponsor
- Takeda
Bipolar Disorder
Asenapine in the Treatment of Older Adults With Bipolar Disorder
Objectives: The investigators propose a first-ever, prospective trial of asenapine in older adults with bipolar disorder (BD) to evaluate effects on mood symptoms, tolerability and functional/general health status.
- Trial name
- NCT01460290
- Testing
- Asenapine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University Hospitals Cleveland Medical Center
Major Depression, Treatment
fMRI Study of Treatment Changes in Major Depression
The overall purposes of this research are to determine if Cognitive Behavioral Therapy (CBT) has the same healing effect on the brain for people with depression as traditional antidepressants do, and in comparison to healthy…
- Trial name
- NCT01027559
- Testing
- Sertraline, Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Bipolar Disorder Depression
Scopolamine in Bipolar Depression
This is a single-site, randomised, double-blind, placebo-controlled, parallel, phase IIb clinical trial. The primary objective of the SCOPE-BD study is to investigate the efficacy and safety of IV Scopolamine, compared to…
- Trial name
- SCOPE-BD (NCT04211961)
- Testing
- Scopolamine
- Where
- Ireland
- Volunteers
- 55 people
- Sponsor
- Dr. Brian Hallahan
Schizophrenia, Schizoaffective Disorder
Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone
Having a diagnosis of schizophrenia or bipolar disorder and being treated with certain of the newer antipsychotics are risk factors for development of diabetes.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00538642
- Testing
- ziprasidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Depression, Postpartum, Anxiety Disorders
Inhaled Oxytocin and HPA Axis Reactivity
Mothers who were enrolled in the Mood, Mother and Infant study will be eligible to participate in the 6-year follow-up maternal visit.
- Conditions
- Depression, Postpartum, Anxiety Disorders, Stress, Psychological
- Trial name
- NCT03593473
- Testing
- Intranasal Oxytocin
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
5-HTP and Creatine for Depression
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression.
- Trial name
- NCT04395183
- Testing
- 5-Hydroxytryptophan 100 MG, Creatine monohydrate
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Utah
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.